首页> 外文期刊>Clinical ophthalmology >Fluoroquinolone antibacterial eye drops: effects on normal human corneal epithelium, stroma, and endothelium
【24h】

Fluoroquinolone antibacterial eye drops: effects on normal human corneal epithelium, stroma, and endothelium

机译:氟喹诺酮类抗菌滴眼剂:对正常人角膜上皮,基质和内皮的影响

获取原文
           

摘要

Background: In vitro studies have suggested the corneal cytotoxicity of third-generation fluoroquinolone levofloxacin (LVFX) and fourth-generation fluoroquinolone moxifloxacin hydrochloride (MFLX) among fluoroquinolone antibacterial eye drops. This study investigated the effects of these two eye drops on the human cornea in vivo.Methods: We evaluated 30 healthy adults (19 men and 11 women, 38.3 ± 6.3 years old). Each subject received an LVFX ophthalmic solution 0.5% in one eye and an MFLX ophthalmic solution 0.5% in the other eye three times daily for 7 days. Functional and morphological corneal changes before and after instillation were evaluated through ophthalmic examinations including breakup time of tear film (BUT) as measured by fluorescein staining and DR-1, Schirmer I test, Heidelberg Retina Tomograph II Rostock Cornea Module (HRTII-RCM), specular microscope, and Pentacum examination.Results: Both the LVFX and MFLX groups had no significant change in each examination before and after instillation. There was also no statistically significant difference in measurements after the 7-day instillation between the groups.Conclusion: Our study results suggest that as with LVFX, MFLX used in a normal clinical setting is unlikely to cause any obvious adverse effects on human normal cornea.
机译:背景:体外研究表明,在氟喹诺酮类抗菌滴眼液中,第三代氟喹诺酮左氧氟沙星(LVFX)和第四代氟喹诺酮莫西沙星盐酸盐(MFLX)的角膜细胞毒性。这项研究调查了这两种滴眼液在体内对人角膜的影响。方法:我们评估了30名健康成年人(19例男性和11例女性,年龄38.3±6.3岁)。每位受试者每天在一只眼中接受0.5%的LVFX眼药水,在另一只眼中接受0.5%的MFLX眼药水,共7天。通过眼科检查评估滴注前后的功能和形态角膜变化,包括通过荧光素染色和DR-1测量的泪膜破裂时间(BUT),Schirmer I测试,Heidelberg Retina Tomograph II Rostock Cornea Module(HRTII-RCM),结果:LVFX组和MFLX组在滴注前后每次检查均无明显变化。两组之间在滴注7天后的测量结果也没有统计学上的显着差异。结论:我们的研究结果表明,与LVFX一样,在正常临床环境中使用MFLX不太可能对人类正常角膜造成任何明显的不良影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号